Brokerage Firm Rating on Medivation (MDVN)

Medivation (MDVN) : 14 analysts are covering Medivation (MDVN) and their average rating on the stock is 1.71, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Medivation (MDVN) : The highest level Medivation (MDVN) is projected to reach is $76 for the short term and the lowest estimate is at $40. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $63.5 and the possibility the share price can swing is $10.04.


For the current week, the company shares have a recommendation consensus of Buy. Medivation (NASDAQ:MDVN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $63.99 and $63.58 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $65.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $65.60, notching a gain of 2.52% for the day. The total traded volume was 3,831,309 . The stock had closed at $63.99 on the previous day.

In a related news, The Securities and Exchange Commission has divulged that Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., had unloaded 2,578 shares at an average price of $60.42 in a transaction dated on June 6, 2016. The total value of the transaction was worth $155,763.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.